|
GS185131: GO:0044699 single-organism process
|
|
GS198398: GO:0050670 regulation of lymphocyte proliferation
|
|
GS184830: GO:0030890 positive regulation of B cell proliferation
|
|
GS202082: GO:0051254 positive regulation of RNA metabolic process
|
|
GS170466: MP:0008211 decreased mature B cell number
|
|
GS167628: MP:0005461 abnormal dendritic cell morphology
|
|
GS169127: MP:0002445 abnormal mononuclear cell differentiation
|
|
GS135258: anti-erythrocyte autoantibody modifier 3 (Aem3, Published QTL Chr 10)
|
|
GS135860: femur breaking strength 3 (Fembrs3, Published QTL Chr 10)
|
|
GS185261: GO:0051254 positive regulation of RNA metabolic process
|
|
GS204481: GO:0070665 positive regulation of leukocyte proliferation
|
|
GS186528: GO:0002684 positive regulation of immune system process
|
|
GS203018: GO:0045935 positive regulation of nucleobase-containing compound metabolic process
|
|
GS168559: MP:0002421 abnormal cell-mediated immunity
|
|
GS168327: MP:0008171 abnormal mature B cell morphology
|
|
GS193152: GO:0032946 positive regulation of mononuclear cell proliferation
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS126475: tert-Butylhydroperoxide interacting genes (MeSH:D020122) in CTD
|
|
GS191193: GO:0009607 response to biotic stimulus
|
|
GS209250: GO:0000080 G1 phase of mitotic cell cycle
|
|
GS136052: IGF-1 serum levels 2 (Igf1sl2, Published QTL Chr 10)
|
|
GS192816: GO:0070491 repressing transcription factor binding
|
|
GS196934: GO:0065008 regulation of biological quality
|
|
GS191669: GO:0001067 regulatory region nucleic acid binding
|
|
GS195061: GO:0051149 positive regulation of muscle cell differentiation
|
|
GS204642: GO:0043543 protein acylation
|
|
GS184570: GO:0016444 somatic cell DNA recombination
|
|
GS180671: GO:0044454 nuclear chromosome part
|
|
GS199273: GO:0043233 organelle lumen
|
|
GS199388: GO:0019901 protein kinase binding
|
|
GS191019: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS201621: GO:0032496 response to lipopolysaccharide
|
|
GS168334: MP:0002619 abnormal lymphocyte morphology
|
|
GS187887: GO:0080090 regulation of primary metabolic process
|
|
GS168382: MP:0001231 abnormal epidermis stratum basale morphology
|
|
GS165643: MP:0011088 partial neonatal lethality
|
|
GS165859: MP:0000351 increased cell proliferation
|
|
GS166858: MP:0000685 abnormal immune system morphology
|
|
GS178814: GO:0046982 protein heterodimerization activity
|
|
GS179950: GO:0006259 DNA metabolic process
|
|
GS163965: MP:0011182 decreased hematopoietic cell number
|
|
GS165850: MP:0000352 decreased cell proliferation
|
|
GS166207: MP:0008180 abnormal marginal zone B cell morphology
|
|
GS200483: GO:0010608 posttranscriptional regulation of gene expression
|
|
GS209602: GO:0051960 regulation of nervous system development
|
|
GS166749: MP:0002221 abnormal lymph organ size
|
|
GS189669: GO:2000112 regulation of cellular macromolecule biosynthetic process
|
|
GS163010: MP:0011181 increased hematopoietic cell number
|
|
GS136165: leishmaniasis resistance 19 (Lmr19, Published QTL Chr 10)
|
|
GS206108: GO:2001141 regulation of RNA biosynthetic process
|
|
GS163376: MP:0009763 increased sensitivity to induced morbidity/mortality
|
|
GS135790: epilepsy 3 (El3, Published QTL Chr 10)
|
|
GS192017: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS184571: GO:0016447 somatic recombination of immunoglobulin gene segments
|
|
GS194417: GO:0000790 nuclear chromatin
|
|
GS177404: GO:0005737 cytoplasm
|
|
GS190282: GO:0050867 positive regulation of cell activation
|
|
GS177265: GO:0048731 system development
|
|
GS207925: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS201251: GO:0044424 intracellular part
|
|
GS193238: GO:0031323 regulation of cellular metabolic process
|
|
GS135751: experimental allergic encephalomyelitis susceptibility 17 (Eae17, Published QTL Chr 10)
|
|
GS178359: GO:0071840 cellular component organization or biogenesis
|
|
GS203908: GO:0016070 RNA metabolic process
|
|
GS181893: GO:0048522 positive regulation of cellular process
|
|
GS170136: MP:0008083 decreased single-positive T cell number
|
|
GS188142: GO:0048856 anatomical structure development
|
|
GS170024: MP:0011086 partial postnatal lethality
|
|
GS136910: vertebral morphology and mechanical traits 15 (Vmmt15, Published QTL Chr 10)
|
|
GS169287: MP:0005090 increased double-negative T cell number
|
|
GS164333: MP:0000516 abnormal renal/urinary system morphology
|
|
GS196988: GO:0045595 regulation of cell differentiation
|
|
GS165866: MP:0000350 abnormal cell proliferation
|
|
GS178357: GO:0071842 cellular component organization at cellular level
|
|
GS162953: MP:0002020 increased tumor incidence
|
|
GS209551: GO:0031981 nuclear lumen
|
|
GS166660: MP:0001731 abnormal postnatal growth
|
|
GS193414: GO:0044249 cellular biosynthetic process
|
|
GS205334: GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
|
|
GS163243: MP:0002362 abnormal spleen marginal zone morphology
|
|
GS194283: GO:0048537 mucosal-associated lymphoid tissue development
|
|
GS197472: GO:0044451 nucleoplasm part
|
|
GS182591: GO:0019900 kinase binding
|
|
GS87096: Table S2: List of Cocaine-Treated HDAC5 KO vs. Cocaine-Treated WT Significantly Regulated Genes. [DRG]
provisional
|
|
GS36044: Neocortex Gene expression correlates of Light-Dark Box Total distance traveled in light and dark compartments in Males BXD
|
|
GS208675: GO:0022403 cell cycle phase
|
|
GS167325: MP:0002144 abnormal B cell differentiation
|
|
GS182978: GO:0033993 response to lipid
|
|
GS193888: GO:0051276 chromosome organization
|
|
GS179236: GO:0048699 generation of neurons
|
|
GS190582: GO:0033152 immunoglobulin V(D)J recombination
|
|
GS188784: GO:0008134 transcription factor binding
|
|
GS178922: GO:0003700 sequence-specific DNA binding transcription factor activity
|
|
GS205659: GO:0042493 response to drug
|
|
GS177844: GO:0002377 immunoglobulin production
|
|
GS194455: GO:0051239 regulation of multicellular organismal process
|
|
GS193937: GO:0006366 transcription from RNA polymerase II promoter
|
|
GS205237: GO:0030217 T cell differentiation
|
|
GS168063: MP:0000313 abnormal cell death
|
|
GS194876: GO:0042113 B cell activation
|
|
GS198868: GO:0000786 nucleosome
|
|
GS179769: GO:0000975 regulatory region DNA binding
|
|
GS135323: apomorphine stress induced climbing 3 (Apsic3, Published QTL Chr 10)
|
|
GS162982: MP:0002357 abnormal spleen white pulp morphology
|
|
GS201367: GO:0019538 protein metabolic process
|
|
GS170415: MP:0008077 abnormal CD8-positive T cell number
|
|
GS198870: GO:0000788 nuclear nucleosome
|
|
GS208716: GO:2000026 regulation of multicellular organismal development
|
|
GS195340: GO:0045893 positive regulation of transcription, DNA-dependent
|
|
GS196808: GO:0032501 multicellular organismal process
|
|
GS178913: GO:0042221 response to chemical stimulus
|
|
GS186744: GO:0043226 organelle
|
|
GS193154: GO:0032944 regulation of mononuclear cell proliferation
|
|
GS136631: small effect CIA locus 5 (Secia5, Published QTL Chr 10)
|
|
GS182835: GO:0005622 intracellular
|
|
GS201756: GO:0042692 muscle cell differentiation
|
|
GS182703: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS195541: GO:0000278 mitotic cell cycle
|
|
GS210178: GO:0031328 positive regulation of cellular biosynthetic process
|
|
GS203482: GO:0044093 positive regulation of molecular function
|
|
GS198360: GO:0006357 regulation of transcription from RNA polymerase II promoter
|
|
GS166202: MP:0008187 absent pro-B cells
|
|
GS186790: GO:0006725 cellular aromatic compound metabolic process
|
|
GS183957: GO:0033077 T cell differentiation in thymus
|
|
GS187423: GO:0031647 regulation of protein stability
|
|
GS166265: MP:0009584 decreased keratinocyte proliferation
|
|
GS194111: GO:0097159 organic cyclic compound binding
|
|
GS167993: MP:0002403 abnormal pre-B cell morphology
|
|
GS208187: GO:0010033 response to organic substance
|
|
GS191988: GO:0070644 vitamin D response element binding
|
|
GS191271: GO:0018205 peptidyl-lysine modification
|
|
GS189141: GO:0030888 regulation of B cell proliferation
|
|
GS185545: GO:0044212 transcription regulatory region DNA binding
|
|
GS168972: MP:0008213 absent immature B cells
|
|
GS194307: GO:0016043 cellular component organization
|
|
GS197666: GO:0051249 regulation of lymphocyte activation
|
|
GS194606: GO:0001779 natural killer cell differentiation
|
|
GS180190: GO:0051329 interphase of mitotic cell cycle
|
|
GS187783: GO:0043543 protein acylation
|
|
GS205645: GO:0008134 transcription factor binding
|
|
GS197222: GO:0031435 mitogen-activated protein kinase kinase kinase binding
|
|
GS189751: GO:0050794 regulation of cellular process
|
|
GS166590: MP:0002873 normal phenotype
|
|
GS187238: GO:0030183 B cell differentiation
|
|
GS202371: GO:0044212 transcription regulatory region DNA binding
|
|
GS187343: GO:0006351 transcription, DNA-dependent
|
|
GS195668: GO:0042221 response to chemical stimulus
|
|
GS207178: GO:0050867 positive regulation of cell activation
|
|
GS126584: Tetrachlorodibenzodioxin interacting genes (MeSH:D013749) in CTD
|
|
GS203369: GO:0005654 nucleoplasm
|
|
GS187175: GO:0045321 leukocyte activation
|
|
GS200950: GO:0018393 internal peptidyl-lysine acetylation
|
|
GS181473: GO:0005488 binding
|
|
GS184445: GO:0044428 nuclear part
|
|
GS180036: GO:0032501 multicellular organismal process
|
|
GS187237: GO:0030182 neuron differentiation
|
|
GS192345: GO:0010628 positive regulation of gene expression
|
|
GS196930: GO:0065007 biological regulation
|
|
GS200312: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS177859: GO:0045944 positive regulation of transcription from RNA polymerase II promoter
|
|
GS191150: GO:0010557 positive regulation of macromolecule biosynthetic process
|
|
GS187615: GO:0070661 leukocyte proliferation
|
|
GS198004: GO:0007399 nervous system development
|
|
GS193227: GO:0030097 hemopoiesis
|
|
GS169389: MP:0002060 abnormal skin morphology
|
|
GS191779: GO:2000026 regulation of multicellular organismal development
|
|
GS164264: MP:0002082 postnatal lethality
|
|
GS167542: MP:0001790 abnormal immune system physiology
|
|
GS167326: MP:0002145 abnormal T cell differentiation
|
|
GS184335: GO:0002200 somatic diversification of immune receptors
|
|
GS204746: GO:0080090 regulation of primary metabolic process
|
|
GS165428: MP:0005153 abnormal B cell proliferation
|
|
GS163601: MP:0002089 abnormal postnatal growth/weight/body size
|
|
GS201249: GO:0044428 nuclear part
|
|
GS196968: GO:0051329 interphase of mitotic cell cycle
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS198456: GO:0019438 aromatic compound biosynthetic process
|
|
GS36034: Neocortex Gene expression correlates of Light-Dark Box Total distance traveled in light and dark compartments in Females & Males BXD
|
|
GS167322: MP:0003944 abnormal T cell subpopulation ratio
|
|
GS194088: GO:0003676 nucleic acid binding
|
|
GS187797: GO:0016570 histone modification
|
|
GS165527: MP:0005378 growth/size phenotype
|
|
GS178589: GO:0045893 positive regulation of transcription, DNA-dependent
|
|
GS178813: GO:0046983 protein dimerization activity
|
|
GS200286: GO:0060284 regulation of cell development
|
|
GS200351: GO:0016569 covalent chromatin modification
|
|
GS169777: MP:0002398 abnormal bone marrow cell morphology/development
|
|
GS136147: lithogenic gene 7 (Lith7, Published QTL Chr 10)
|
|
GS167503: MP:0003054 spina bifida
|
|
GS177598: GO:0043412 macromolecule modification
|
|
GS186740: GO:0043229 intracellular organelle
|
|
GS169409: MP:0004939 abnormal B cell morphology
|
|
GS196540: GO:0043565 sequence-specific DNA binding
|
|
GS166250: MP:0008247 abnormal mononuclear cell morphology
|
|
GS199538: GO:0018193 peptidyl-amino acid modification
|
|
GS188506: GO:0010467 gene expression
|
|
GS208012: GO:0044464 cell part
|
|
GS201239: GO:0046483 heterocycle metabolic process
|
|
GS136778: systolic blood pressure 1 (Sysbp1, Published QTL Chr 10)
|
|
GS192073: GO:1901576 organic substance biosynthetic process
|
|
GS188399: GO:0044238 primary metabolic process
|
|
GS162983: MP:0002356 abnormal spleen red pulp morphology
|
|
GS208060: GO:0010557 positive regulation of macromolecule biosynthetic process
|
|
GS184435: GO:0046483 heterocycle metabolic process
|
|
GS169063: MP:0005432 abnormal pro-B cell morphology
|
|
GS168422: MP:0000716 abnormal immune system cell morphology
|
|
GS195113: GO:0071841 cellular component organization or biogenesis at cellular level
|
|
GS205567: GO:0045787 positive regulation of cell cycle
|
|
GS123554: vinclozolin interacting genes (MeSH:C025643) in CTD
|
|
GS186214: GO:0048518 positive regulation of biological process
|
|
GS168152: MP:0005501 abnormal skin physiology
|
|
GS205144: GO:0048468 cell development
|
|
GS206764: GO:0048541 Peyer's patch development
|
|
GS35773: Hippocampus Gene expression correlates of CPP - Time (s) in drug-paired compartment a in Females BXD
|
|
GS166719: MP:0010678 abnormal skin adnexa morphology
|
|
GS123718: Ethinyl Estradiol interacting genes (MeSH:D004997) in CTD
|
|
GS177310: GO:1901360 organic cyclic compound metabolic process
|
|
GS167508: MP:0008761 abnormal immunoglobulin light chain V-J recombination
|
|
GS206175: GO:0051318 G1 phase
|
|
GS163241: MP:0002367 abnormal thymus lobule morphology
|
|
GS167020: MP:0003956 abnormal body size
|
|
GS162986: MP:0001802 arrested B cell differentiation
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS192959: GO:0002237 response to molecule of bacterial origin
|
|
GS169833: MP:0005380 embryogenesis phenotype
|
|
GS204096: GO:0030183 B cell differentiation
|
|
GS177902: GO:0042802 identical protein binding
|
|
GS208657: GO:0008284 positive regulation of cell proliferation
|
|
GS191151: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS196002: GO:0048699 generation of neurons
|
|
GS209282: GO:0010628 positive regulation of gene expression
|
|
GS163283: MP:0008040 decreased NK T cell number
|
|
GS197016: GO:0032991 macromolecular complex
|
|
GS178448: GO:0005634 nucleus
|
|
GS198948: GO:0006310 DNA recombination
|
|
GS199635: GO:0005622 intracellular
|
|
GS195206: GO:0002520 immune system development
|
|
GS163591: MP:0005015 increased T cell number
|
|
GS183284: GO:0003713 transcription coactivator activity
|
|
GS188798: GO:0042493 response to drug
|
|
GS208061: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS165986: MP:0008463 abnormal peripheral lymph node morphology
|
|
GS213076: Genes with suggestive difference in (B6) vs (B6PF1 + PB6F1 + PWD) comparison
|
|
GS163077: MP:0010274 increased organ/body region tumor incidence
|
|
GS187984: GO:0003682 chromatin binding
|
|
GS170419: MP:0008078 increased CD8-positive T cell number
|
|
GS168379: MP:0002151 abnormal neural tube morphology/development
|
|
GS135635: collagen induced arthritis QTL 8 (Cia8, Published QTL Chr 10)
|
|
GS165244: MP:0010771 integument phenotype
|
|
GS196941: GO:0008150 biological_process
|
|
GS164673: MP:0010296 increased hemolymphoid system tumor incidence
|
|
GS135699: directional asymmetry QTL 6 (Daq6, Published QTL Chr 10)
|
|
GS207176: GO:0050865 regulation of cell activation
|
|
GS190893: GO:0030154 cell differentiation
|
|
GS197470: GO:0044454 nuclear chromosome part
|
|
GS166564: MP:0000692 small spleen
|
|
GS201256: GO:0044422 organelle part
|
|
GS35807: Striatum Gene expression correlates of Cocaine CPP- Time (s) in drug-paired compartment a in Males BXD
|
|
GS201431: GO:0005515 protein binding
|
|
GS135438: bone mineral density 38 (Bmd38, Published QTL Chr 10)
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS136941: vertebral trabecular bone trait 9 (Vtbt9, Published QTL Chr 10)
|
|
GS209411: GO:0048869 cellular developmental process
|
|
GS187160: GO:0044707 single-multicellular organism process
|
|
GS177548: GO:0048534 hematopoietic or lymphoid organ development
|
|
GS177761: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS177169: GO:0051276 chromosome organization
|
|
GS189309: GO:0051318 G1 phase
|
|
GS203371: GO:0002684 positive regulation of immune system process
|
|
GS168630: MP:0000377 abnormal hair follicle morphology
|
|
GS199267: GO:0043234 protein complex
|
|
GS165880: MP:0001218 thin epidermis
|
|
GS201372: GO:0016444 somatic cell DNA recombination
|
|
GS181783: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS195110: GO:0071842 cellular component organization at cellular level
|
|
GS193059: GO:0044446 intracellular organelle part
|
|
GS210181: GO:0031325 positive regulation of cellular metabolic process
|
|
GS209564: GO:0043231 intracellular membrane-bounded organelle
|
|
GS202080: GO:0051252 regulation of RNA metabolic process
|
|
GS208051: GO:0002521 leukocyte differentiation
|
|
GS184781: GO:0009617 response to bacterium
|
|
GS181609: GO:0050671 positive regulation of lymphocyte proliferation
|
|
GS169827: MP:0005387 immune system phenotype
|
|
GS204095: GO:0030182 neuron differentiation
|
|
GS167073: MP:0001926 female infertility
|
|
GS199272: GO:0043232 intracellular non-membrane-bounded organelle
|
|
GS177988: GO:0030165 PDZ domain binding
|
|
GS165181: MP:0010365 increased thymus tumor incidence
|
|
GS194524: GO:0006325 chromatin organization
|
|
GS204021: GO:0044707 single-multicellular organism process
|
|
GS205047: GO:0006807 nitrogen compound metabolic process
|
|
GS184629: GO:0005515 protein binding
|
|
GS192088: GO:0000989 transcription factor binding transcription factor activity
|
|
GS204287: GO:0031647 regulation of protein stability
|
|
GS169603: MP:0001672 abnormal embryogenesis/ development
|
|
GS164482: MP:0001216 abnormal epidermal layer morphology
|
|
GS178785: GO:0000278 mitotic cell cycle
|
|
GS188441: GO:0045165 cell fate commitment
|
|
GS135614: circulating hormone level QTL 6 (Chlq6, Published QTL Chr 10)
|
|
GS194481: GO:0019899 enzyme binding
|
|
GS183680: GO:0010608 posttranscriptional regulation of gene expression
|
|
GS186488: GO:0048513 organ development
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS166718: MP:0002169 no abnormal phenotype detected
|
|
GS84241: alcohol preference (Published QTL, Chr 10)
|
|
GS196806: GO:0032502 developmental process
|
|
GS204842: GO:0003682 chromatin binding
|
|
GS206618: GO:0050793 regulation of developmental process
|
|
GS166215: MP:0008188 abnormal transitional stage B cell morphology
|
|
GS168273: MP:0002432 abnormal CD4-positive T cell morphology
|
|
GS181215: GO:0007399 nervous system development
|
|
GS186642: GO:0051707 response to other organism
|
|
GS201592: GO:0009617 response to bacterium
|
|
GS189941: GO:0043425 bHLH transcription factor binding
|
|
GS164022: MP:0008246 abnormal leukocyte morphology
|
|
GS166587: MP:0003643 spleen atrophy
|
|
GS194586: GO:0002376 immune system process
|
|
GS209009: GO:1901576 organic substance biosynthetic process
|
|
GS182705: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS204036: GO:0045321 leukocyte activation
|
|
GS181102: GO:0043228 non-membrane-bounded organelle
|
|
GS164742: MP:0001732 postnatal growth retardation
|
|
GS166405: MP:0002111 abnormal tail morphology
|
|
GS197319: GO:0003712 transcription cofactor activity
|
|
GS182194: GO:0005667 transcription factor complex
|
|
GS189546: GO:0002440 production of molecular mediator of immune response
|
|
GS170545: MP:0002022 increased lymphoma incidence
|
|
GS207457: GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
|
|
GS135326: age related thymic involution 2 (Arti2, Published QTL Chr 10)
|
|
GS167098: MP:0001819 abnormal immune cell physiology
|
|
GS177356: GO:0003674 molecular_function
|
|
GS203590: GO:0043229 intracellular organelle
|
|
GS199032: GO:0036211 protein modification process
|
|
GS177717: GO:0051239 regulation of multicellular organismal process
|
|
GS177309: GO:1901363 heterocyclic compound binding
|
|
GS196837: GO:0042110 T cell activation
|
|
GS136072: insulin QTL 4 (Insq4, Published QTL Chr 10)
|
|
GS188410: GO:0032774 RNA biosynthetic process
|
|
GS192471: GO:0048869 cellular developmental process
|
|
GS191727: GO:0008283 cell proliferation
|
|
GS198399: GO:0050671 positive regulation of lymphocyte proliferation
|
|
GS198991: GO:0005667 transcription factor complex
|
|
GS210095: GO:0032943 mononuclear cell proliferation
|
|
GS182740: GO:0018193 peptidyl-amino acid modification
|
|
GS203072: GO:0090304 nucleic acid metabolic process
|
|
GS180063: GO:0042110 T cell activation
|
|
GS168988: MP:0005089 decreased double-negative T cell number
|
|
GS177382: GO:0097159 organic cyclic compound binding
|
|
GS201253: GO:0044427 chromosomal part
|
|
GS191662: GO:0033151 V(D)J recombination
|
|
GS202077: GO:0051251 positive regulation of lymphocyte activation
|
|
GS202813: GO:0006475 internal protein amino acid acetylation
|
|
GS168848: MP:0002452 abnormal antigen presenting cell physiology
|
|
GS205543: GO:0070013 intracellular organelle lumen
|
|
GS177903: GO:0042803 protein homodimerization activity
|
|
GS168330: MP:0008176 abnormal germinal center B cell morphology
|
|
GS170413: MP:0008071 absent B cells
|
|
GS187751: GO:0019222 regulation of metabolic process
|
|
GS183491: GO:0060284 regulation of cell development
|
|
GS196719: GO:0006259 DNA metabolic process
|
|
GS191144: GO:0002521 leukocyte differentiation
|
|
GS136675: skull morphology 14 (Skull14, Published QTL Chr 10)
|
|
GS180238: GO:0032993 protein-DNA complex
|
|
GS136235: mandible length 9 (Manln9, Published QTL Chr 10)
|
|
GS135606: circulating hormone level QTL 15 (Chlq15, Published QTL Chr 10)
|
|
GS193237: GO:0031325 positive regulation of cellular metabolic process
|
|
GS195214: GO:0009987 cellular process
|
|
GS207177: GO:0050864 regulation of B cell activation
|
|
GS163557: MP:0008038 abnormal NK T cell number
|
|
GS163934: MP:0001764 abnormal homeostasis
|
|
GS184452: GO:0044422 organelle part
|
|
GS204204: GO:0006351 transcription, DNA-dependent
|
|
GS180034: GO:0032502 developmental process
|
|
GS195112: GO:0071840 cellular component organization or biogenesis
|
|
GS200648: GO:0044260 cellular macromolecule metabolic process
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS177863: GO:0001779 natural killer cell differentiation
|
|
GS180155: GO:0065009 regulation of molecular function
|
|
GS206571: GO:0045666 positive regulation of neuron differentiation
|
|
GS169025: MP:0001657 abnormal induced morbidity/mortality
|
|
GS188478: GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
|
|
GS194602: GO:0045944 positive regulation of transcription from RNA polymerase II promoter
|
|
GS165649: MP:0008127 decreased dendritic cell number
|
|
GS200755: GO:0033077 T cell differentiation in thymus
|
|
GS125002: Topotecan interacting genes (MeSH:D019772) in CTD
|
|
GS185259: GO:0051252 regulation of RNA metabolic process
|
|
GS203642: GO:0006725 cellular aromatic compound metabolic process
|
|
GS190280: GO:0050865 regulation of cell activation
|
|
GS188381: GO:0030217 T cell differentiation
|
|
GS168174: MP:0001919 abnormal reproductive system physiology
|
|
GS181133: GO:0046649 lymphocyte activation
|
|
GS207923: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS165265: MP:0005014 increased B cell number
|
|
GS198263: GO:0005488 binding
|
|
GS196935: GO:0051325 interphase
|
|
GS194040: GO:1901360 organic cyclic compound metabolic process
|
|
GS193009: GO:0042127 regulation of cell proliferation
|
|
GS86932: Table S3: CORTEX 17K MICROARRAY [DRG]
|
|
GS192918: GO:0050896 response to stimulus
|
|
GS184574: GO:0043967 histone H4 acetylation
|
|
GS164782: MP:0009543 abnormal thymus corticomedullary boundary morphology
|
|
GS190067: GO:0018130 heterocycle biosynthetic process
|
|
GS165524: MP:0010769 abnormal survival
|
|
GS180526: GO:0003712 transcription cofactor activity
|
|
GS170417: MP:0008075 decreased CD4-positive T cell number
|
|
GS163280: MP:0008043 abnormal NK cell number
|
|
GS208597: GO:0033151 V(D)J recombination
|
|
GS170092: MP:0000709 enlarged thymus
|
|
GS205266: GO:0032774 RNA biosynthetic process
|
|
GS170617: MP:0005022 abnormal immature B cell morphology
|
|
GS165243: MP:0010770 preweaning lethality
|
|
GS164429: MP:0010288 increased gland tumor incidence
|
|
GS177959: GO:0051726 regulation of cell cycle
|
|
GS167999: MP:0002408 abnormal double-positive T cell morphology
|
|
GS125403: Diethylstilbestrol interacting genes (MeSH:D004054) in CTD
|
|
GS179777: GO:0043565 sequence-specific DNA binding
|
|
GS177784: GO:0006325 chromatin organization
|
|
GS205691: GO:0022008 neurogenesis
|
|
GS194267: GO:0043170 macromolecule metabolic process
|
|
GS210357: GO:0044249 cellular biosynthetic process
|
|
GS180452: GO:0044237 cellular metabolic process
|
|
GS183630: GO:0002682 regulation of immune system process
|
|
GS178453: GO:0002520 immune system development
|
|
GS164694: MP:0005048 thrombosis
|
|
GS168270: MP:0002435 abnormal effector T cell morphology
|
|
GS182469: GO:0043234 protein complex
|
|
GS195570: GO:0046983 protein dimerization activity
|
|
GS206953: GO:0018130 heterocycle biosynthetic process
|
|
GS203057: GO:0048518 positive regulation of biological process
|
|
GS165798: MP:0005367 renal/urinary system phenotype
|
|
GS167589: MP:0005016 decreased lymphocyte cell number
|
|
GS194499: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS123768: Cyclosporine interacting genes (MeSH:D016572) in CTD
|
|
GS180164: GO:0008150 biological_process
|
|
GS177357: GO:0003676 nucleic acid binding
|
|
GS168995: MP:0009642 abnormal blood homeostasis
|
|
GS177531: GO:0043170 macromolecule metabolic process
|
|
GS188287: GO:0048468 cell development
|
|
GS196986: GO:0045597 positive regulation of cell differentiation
|
|
GS208674: GO:0022402 cell cycle process
|
|
GS206415: GO:0002440 production of molecular mediator of immune response
|
|
GS209023: GO:0000989 transcription factor binding transcription factor activity
|
|
GS189746: GO:0050793 regulation of developmental process
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS192660: GO:0051960 regulation of nervous system development
|
|
GS167575: MP:0005013 increased lymphocyte cell number
|
|
GS170543: MP:0002024 T cell derived lymphoma
|
|
GS177214: GO:0006366 transcription from RNA polymerase II promoter
|
|
GS180236: GO:0032991 macromolecular complex
|
|
GS164776: MP:0008178 decreased germinal center B cell number
|
|
GS207858: GO:0009059 macromolecule biosynthetic process
|
|
GS87041: Table S3: List of Cocaine-Treated HDAC5 KO vs. Saline-Treated HDAC5 KO Significantly Regulated Genes. [DRG]
provisional
|
|
GS163560: MP:0008037 abnormal T cell morphology
|
|
GS177813: GO:0031974 membrane-enclosed lumen
|
|
GS184218: GO:0071704 organic substance metabolic process
|
|
GS164605: MP:0002339 abnormal lymph node morphology
|
|
GS192610: GO:0031981 nuclear lumen
|
|
GS200602: GO:0044267 cellular protein metabolic process
|
|
GS163568: MP:0002551 abnormal blood coagulation
|
|
GS187616: GO:0070663 regulation of leukocyte proliferation
|
|
GS200080: GO:0003713 transcription coactivator activity
|
|
GS136454: postnatal body weight growth 16 (Pbwg16, Published QTL Chr 10)
|
|
GS183514: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS866: Linear decrease in expression in both Pax6 (Sey) mutants and controls.
|
|
GS183848: GO:0044260 cellular macromolecule metabolic process
|
|
GS186757: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS164257: MP:0002085 abnormal embryonic tissue morphology
|
|
GS169371: MP:0000929 open neural tube
|
|
GS167566: MP:0005018 decreased T cell number
|
|
GS198685: GO:0048522 positive regulation of cellular process
|
|
GS170086: MP:0000703 abnormal thymus morphology
|
|
GS201949: GO:0044699 single-organism process
|
|
GS136720: susceptibility to lung cancer 22 (Sluc22, Published QTL Chr 10)
|
|
GS170089: MP:0000706 small thymus
|
|
GS208954: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS202902: GO:0050871 positive regulation of B cell activation
|
|
GS186526: GO:0005654 nucleoplasm
|
|
GS135645: cardiac modifier of nmd 2 (Cmn2, Published QTL Chr 10)
|
|
GS190950: GO:0009059 macromolecule biosynthetic process
|
|
GS181568: GO:0006357 regulation of transcription from RNA polymerase II promoter
|
|
GS164320: MP:0003861 abnormal nervous system development
|
|
GS178461: GO:0009987 cellular process
|
|
GS163966: MP:0002098 abnormal vibrissa morphology
|
|
GS192624: GO:0043231 intracellular membrane-bounded organelle
|
|
GS205296: GO:0045165 cell fate commitment
|
|
GS165620: MP:0008125 abnormal dendritic cell number
|
|
GS186743: GO:0043227 membrane-bounded organelle
|
|
GS124185: Plant Extracts interacting genes (MeSH:D010936) in CTD
|
|
GS136079: juvenile cystic kidney modifier 1 (Jckm1, Published QTL Chr 10)
|
|
GS167996: MP:0002407 abnormal double-negative T cell morphology
|
|
GS169973: MP:0002006 tumorigenesis
|
|
GS179830: GO:0006464 cellular protein modification process
|
|
GS201373: GO:0016447 somatic recombination of immunoglobulin gene segments
|
|
GS193268: GO:0005575 cellular_component
|
|
GS194039: GO:1901363 heterocyclic compound binding
|
|
GS170546: MP:0002021 increased incidence of induced tumors
|
|
GS188190: GO:0006807 nitrogen compound metabolic process
|
|
GS135450: bone length and organs 6 (Bod6, Published QTL Chr 10)
|
|
GS194646: GO:0042803 protein homodimerization activity
|
|
GS186246: GO:0018394 peptidyl-lysine acetylation
|
|
GS200436: GO:0030101 natural killer cell activation
|
|
GS207797: GO:0030154 cell differentiation
|
|
GS207581: GO:0007275 multicellular organismal development
|
|
GS184149: GO:0018393 internal peptidyl-lysine acetylation
|
|
GS191721: GO:0008284 positive regulation of cell proliferation
|
|
GS205002: GO:0048856 anatomical structure development
|
|
GS164881: MP:0005068 abnormal NK cell morphology
|
|
GS170364: MP:0000715 decreased thymocyte number
|
|
GS166746: MP:0002224 abnormal spleen size
|
|
GS86494: Table S1: Hippocampus 17 K microarray data. [DRG]
|
|
GS207857: GO:0009058 biosynthetic process
|
|
GS170358: MP:0001823 thymus hypoplasia
|
|
GS192986: GO:0006996 organelle organization
|
|
GS201142: GO:0002200 somatic diversification of immune receptors
|
|
GS136650: skeletal size (tail length) 4 (Skl4, Published QTL Chr 10)
|
|
GS165466: MP:0003632 abnormal nervous system morphology
|
|
GS163956: MP:0011180 abnormal hematopoietic cell number
|
|
GS169835: MP:0005389 reproductive system phenotype
|
|
GS200490: GO:0061061 muscle structure development
|
|
GS190564: GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
|
|
GS203238: GO:0000228 nuclear chromosome
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS196595: GO:0006464 cellular protein modification process
|
|
GS166706: MP:0002166 altered tumor susceptibility
|
|
GS184566: GO:0019538 protein metabolic process
|
|
GS201088: GO:0002326 B cell lineage commitment
|
|
GS201191: GO:0042100 B cell proliferation
|
|
GS191106: GO:0044464 cell part
|
|
GS177570: GO:0016043 cellular component organization
|
|
GS180431: GO:0031435 mitogen-activated protein kinase kinase kinase binding
|
|
GS186227: GO:0090304 nucleic acid metabolic process
|
|
GS127205: Tamoxifen interacting genes (MeSH:D013629) in CTD
|
|
GS167991: MP:0002401 abnormal lymphopoiesis
|
|
GS204612: GO:0019222 regulation of metabolic process
|
|
GS210168: GO:0030098 lymphocyte differentiation
|
|
GS167507: MP:0008760 abnormal immunoglobulin heavy chain V(D)J recombination
|
|
GS177862: GO:0001775 cell activation
|
|
GS178247: GO:0070888 E-box binding
|
|
GS170460: MP:0008217 abnormal B cell activation
|
|
GS84243: METH responses for home cage activity (Published QTL, Chr 10)
|
|
GS183635: GO:0030101 natural killer cell activation
|
|
GS192944: GO:0050767 regulation of neurogenesis
|
|
GS194555: GO:0031974 membrane-enclosed lumen
|
|
GS184449: GO:0044427 chromosomal part
|
|
GS191738: GO:0022403 cell cycle phase
|
|
GS164133: MP:0005076 abnormal cell differentiation
|
|
GS190772: GO:0002696 positive regulation of leukocyte activation
|
|
GS177680: GO:0000790 nuclear chromatin
|
|
GS210099: GO:0032944 regulation of mononuclear cell proliferation
|
|
GS181074: GO:0043966 histone H3 acetylation
|
|
GS169133: MP:0002442 abnormal leukocyte physiology
|
|
GS206601: GO:0050821 protein stabilization
|
|
GS203607: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS135360: B.burgdorferi-associated arthritis 18 (Bbaa18, Published QTL Chr 10)
|
|
GS201376: GO:0043967 histone H4 acetylation
|
|
GS203494: GO:0051704 multi-organism process
|
|
GS185585: GO:0044710 single-organism metabolic process
|
|
GS187708: GO:0009893 positive regulation of metabolic process
|
|
GS209762: GO:0070491 repressing transcription factor binding
|
|
GS204232: GO:0001071 nucleic acid binding transcription factor activity
|
|
GS135778: endothelin receptor type B modifier 1 (Ednrbm1, Published QTL Chr 10)
|
|
GS187618: GO:0070665 positive regulation of leukocyte proliferation
|
|
GS168502: MP:0002058 neonatal lethality
|
|
GS36064: Neocortex Gene expression correlates of Light-Dark Box Transitions in Females & Males BXD
|
|
GS136122: life span 2 (Lifespan2, Published QTL Chr 10)
|
|
GS205338: GO:0051094 positive regulation of developmental process
|
|
GS184809: GO:0032496 response to lipopolysaccharide
|
|
GS182595: GO:0019904 protein domain specific binding
|
|
GS170084: MP:0000701 abnormal lymph node size
|
|
GS136154: limb length QTL 4 (Lmblgq4, Published QTL Chr 10)
|
|
GS188482: GO:0051094 positive regulation of developmental process
|
|
GS180156: GO:0065008 regulation of biological quality
|
|
GS204479: GO:0070663 regulation of leukocyte proliferation
|
|
GS192089: GO:0000988 protein binding transcription factor activity
|
|
GS197892: GO:0043228 non-membrane-bounded organelle
|
|
GS165904: MP:0009622 absent inguinal lymph nodes
|
|
GS192256: GO:0007049 cell cycle
|
|
GS206822: GO:0043425 bHLH transcription factor binding
|
|
GS195643: GO:0003677 DNA binding
|
|
GS198572: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS209928: GO:0006996 organelle organization
|
|
GS167077: MP:0008082 increased single-positive T cell number
|
|
GS196532: GO:0000975 regulatory region DNA binding
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS206544: GO:2000112 regulation of cellular macromolecule biosynthetic process
|
|
GS187798: GO:0016573 histone acetylation
|
|
GS170411: MP:0008073 abnormal CD4-positive T cell number
|
|
GS194133: GO:0005737 cytoplasm
|
|
GS167627: MP:0005460 abnormal leukopoiesis
|
|
GS199501: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS185489: GO:0046651 lymphocyte proliferation
|
|
GS184130: GO:0006473 protein acetylation
|
|
GS206329: GO:0060255 regulation of macromolecule metabolic process
|
|
GS184280: GO:0002326 B cell lineage commitment
|
|
GS195199: GO:0005634 nucleus
|
|
GS193234: GO:0031328 positive regulation of cellular biosynthetic process
|
|
GS163728: MP:0005154 increased B cell proliferation
|
|
GS192315: GO:0000080 G1 phase of mitotic cell cycle
|
|
GS208927: GO:0070644 vitamin D response element binding
|
|
GS163803: MP:0003631 nervous system phenotype
|
|
GS207474: GO:0033152 immunoglobulin V(D)J recombination
|
|
GS169285: MP:0005092 decreased double-positive T cell number
|
|
GS136004: hepatocarcinogen resistance 2 (Hpcr2, Published QTL Chr 10)
|
|
GS189240: GO:2001141 regulation of RNA biosynthetic process
|
|
GS170020: MP:0008215 decreased immature B cell number
|
|
GS208914: GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
|
|
GS135312: aortic lesion size 1 (Aorls1, Published QTL Chr 10)
|
|
GS186178: GO:0045935 positive regulation of nucleobase-containing compound metabolic process
|
|
GS170647: MP:0002340 abnormal axillary lymph node morphology
|
|
GS181608: GO:0050670 regulation of lymphocyte proliferation
|
|
GS202313: GO:0046651 lymphocyte proliferation
|
|
GS190281: GO:0050864 regulation of B cell activation
|
|
GS209951: GO:0042127 regulation of cell proliferation
|
|
GS195571: GO:0046982 protein heterodimerization activity
|
|
GS204478: GO:0070661 leukocyte proliferation
|
|
GS184384: GO:0042100 B cell proliferation
|
|
GS185492: GO:0050789 regulation of biological process
|
|
GS167714: MP:0002414 abnormal myeloblast morphology/development
|
|
GS167067: MP:0002217 small lymph nodes
|
|
GS213077: Genes with suggestive difference in (PWD) vs (PB6F1 + B6PF1 + B6) comparison
|
|
GS186645: GO:0051704 multi-organism process
|
|
GS210170: GO:0030097 hemopoiesis
|
|
GS185975: GO:0006475 internal protein amino acid acetylation
|
|
GS209902: GO:0002237 response to molecule of bacterial origin
|
|
GS182590: GO:0019901 protein kinase binding
|
|
GS191975: GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
|
|
GS193991: GO:0048731 system development
|
|
GS201642: GO:0030890 positive regulation of B cell proliferation
|
|
GS163294: MP:0000218 increased leukocyte cell number
|
|
GS182153: GO:0006310 DNA recombination
|
|
GS165209: MP:0005010 abnormal CD8-positive T cell morphology
|
|
GS181667: GO:0019438 aromatic compound biosynthetic process
|
|
GS188511: GO:0010468 regulation of gene expression
|
|
GS34223: Neocortex Gene expression correlates of Light-Dark Box Total distance traveled in light compartment in Males BXD
|
|
GS165099: MP:0008209 decreased pre-B cell number
|
|
GS125548: Doxorubicin interacting genes (MeSH:D004317) in CTD
|
|
GS84242: ethanol withdrawal (Published QTL, Chr 10)
|
|
GS124083: polyphenols interacting genes (MeSH:C025299) in CTD
|
|
GS169767: MP:0002396 abnormal hematopoietic system morphology/development
|
|
GS184447: GO:0044424 intracellular part
|
|
GS193236: GO:0031326 regulation of cellular biosynthetic process
|
|
GS184569: GO:0016445 somatic diversification of immunoglobulins
|
|
GS207673: GO:0002694 regulation of leukocyte activation
|
|
GS209863: GO:0050896 response to stimulus
|
|
GS166513: MP:0008195 abnormal antigen presenting cell morphology
|
|
GS169880: MP:0009676 abnormal hemostasis
|
|
GS163080: MP:0010273 increased classified tumor incidence
|
|
GS178360: GO:0071841 cellular component organization or biogenesis at cellular level
|
|
GS135339: atherosclerosis 17 (Ath17, Published QTL Chr 10)
|
|
GS191021: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS199499: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS203335: GO:0048513 organ development
|
|
GS188684: GO:0070013 intracellular organelle lumen
|
|
GS178127: GO:0042113 B cell activation
|
|
GS166712: MP:0002161 abnormal fertility/fecundity
|
|
GS163589: MP:0005017 decreased B cell number
|
|
GS163240: MP:0002364 abnormal thymus size
|
|
GS193225: GO:0030098 lymphocyte differentiation
|
|
GS203092: GO:0018394 peptidyl-lysine acetylation
|
|
GS36074: Neocortex Gene expression correlates of Light-Dark Box Transitions in Males BXD
|
|
GS182475: GO:0043233 organelle lumen
|
|
GS182234: GO:0036211 protein modification process
|
|
GS164534: MP:0002019 abnormal tumor incidence
|
|
GS210212: GO:0005575 cellular_component
|
|
GS195291: GO:0006355 regulation of transcription, DNA-dependent
|
|
GS204656: GO:0016570 histone modification
|
|
GS135500: brain size control 1 (Bsc1, Published QTL Chr 10)
|
|
GS205369: GO:0010468 regulation of gene expression
|
|
GS164304: MP:0004808 abnormal hematopoietic stem cell morphology
|
|
GS163845: MP:0000238 absent pre-B cells
|
|
GS188762: GO:0009889 regulation of biosynthetic process
|
|
GS206623: GO:0050794 regulation of cellular process
|
|
GS124805: decitabine interacting genes (MeSH:C014347) in CTD
|
|
GS197924: GO:0046649 lymphocyte activation
|
|
GS177547: GO:0048537 mucosal-associated lymphoid tissue development
|
|
GS194995: GO:0070888 E-box binding
|
|
GS186395: GO:0000228 nuclear chromosome
|
|
GS189724: GO:0050821 protein stabilization
|
|
GS125820: 4-hydroxy-2-nonenal interacting genes (MeSH:C027576) in CTD
|
|
GS187370: GO:0001071 nucleic acid binding transcription factor activity
|
|
GS163818: MP:0002722 abnormal immune system organ morphology
|
|
GS197864: GO:0043966 histone H3 acetylation
|
|
GS182076: GO:0000786 nucleosome
|
|
GS164261: MP:0002081 perinatal lethality
|
|
GS194038: GO:1901362 organic cyclic compound biosynthetic process
|
|
GS194703: GO:0051726 regulation of cell cycle
|
|
GS199778: GO:0033993 response to lipid
|
|
GS197018: GO:0032993 protein-DNA complex
|
|
GS206007: GO:0030888 regulation of B cell proliferation
|
|
GS183803: GO:0044267 cellular protein metabolic process
|
|
GS193150: GO:0032943 mononuclear cell proliferation
|
|
GS177742: GO:0019899 enzyme binding
|
|
GS135247: adiposity 15 (Adip15, Published QTL Chr 10)
|
|
GS136099: long bones 9 (Lbn9, Published QTL Chr 10)
|
|
GS203491: GO:0051707 response to other organism
|
|
GS200930: GO:0006473 protein acetylation
|
|
GS164588: MP:0003051 curly tail
|
|
GS168294: MP:0003699 abnormal female reproductive system physiology
|
|
GS164263: MP:0002083 premature death
|
|
GS210180: GO:0031326 regulation of cellular biosynthetic process
|
|
GS189880: GO:0048541 Peyer's patch development
|
|
GS135327: arthropathy in MRL and DBA/1 mice 1 (Artmd1, Published QTL Chr 10)
|
|
GS182834: GO:0005623 cell
|
|
GS205622: GO:0009889 regulation of biosynthetic process
|
|
GS189460: GO:0060255 regulation of macromolecule metabolic process
|
|
GS168845: MP:0002459 abnormal B cell physiology
|
|
GS182474: GO:0043232 intracellular non-membrane-bounded organelle
|
|
GS168012: MP:0010832 lethality during fetal growth through weaning
|
|
GS201371: GO:0016445 somatic diversification of immunoglobulins
|
|
GS208190: GO:0018205 peptidyl-lysine modification
|
|
GS167075: MP:0001924 infertility
|
|
GS169963: MP:0001284 absent vibrissae
|
|
GS178537: GO:0006355 regulation of transcription, DNA-dependent
|
|
GS185937: GO:0005694 chromosome
|
|
GS196943: GO:0008152 metabolic process
|
|
GS190770: GO:0002694 regulation of leukocyte activation
|
|
GS199634: GO:0005623 cell
|
|
GS164136: MP:0000001 mammalian phenotype
|
|
GS191737: GO:0022402 cell cycle process
|
|
GS187045: GO:0016070 RNA metabolic process
|
|
GS210097: GO:0032946 positive regulation of mononuclear cell proliferation
|
|
GS210182: GO:0031323 regulation of cellular metabolic process
|
|
GS163026: MP:0000221 decreased leukocyte cell number
|
|
GS208107: GO:0009607 response to biotic stimulus
|
|
GS170761: MP:0009628 absent brachial lymph nodes
|
|
GS196933: GO:0065009 regulation of molecular function
|
|
GS206569: GO:0045664 regulation of neuron differentiation
|
|
GS166683: MP:0005231 abnormal brachial lymph node morphology
|
|
GS180206: GO:0045597 positive regulation of cell differentiation
|
|
GS190682: GO:0007275 multicellular organismal development
|
|
GS182078: GO:0000788 nuclear nucleosome
|
|
GS168551: MP:0002429 abnormal blood cell morphology/development
|
|
GS166518: MP:0008190 decreased transitional stage B cell number
|
|
GS182074: GO:0000785 chromatin
|
|
GS168560: MP:0002420 abnormal adaptive immunity
|
|
GS207675: GO:0002696 positive regulation of leukocyte activation
|
|
GS180208: GO:0045595 regulation of cell differentiation
|
|
GS188826: GO:0022008 neurogenesis
|
|
GS170138: MP:0008081 abnormal single-positive T cell number
|
|
GS170107: MP:0003720 abnormal neural tube closure
|
|
GS204568: GO:0009893 positive regulation of metabolic process
|
|
GS163297: MP:0000217 abnormal leukocyte cell number
|
|
GS177843: GO:0002376 immune system process
|
|
GS183552: GO:0016568 chromatin modification
|
|
GS168118: MP:0001191 abnormal skin condition
|
|
GS200350: GO:0016568 chromatin modification
|
|
GS202775: GO:0005694 chromosome
|
|
GS194645: GO:0042802 identical protein binding
|
|
GS180157: GO:0051325 interphase
|
|
GS180152: GO:0065007 biological regulation
|
|
GS189694: GO:0045666 positive regulation of neuron differentiation
|
|
GS165536: MP:0005371 limbs/digits/tail phenotype
|
|
GS165397: MP:0001265 decreased body size
|
|
GS170465: MP:0008210 increased mature B cell number
|
|
GS169485: MP:0000726 absent lymphocyte
|
|
GS194284: GO:0048534 hematopoietic or lymphoid organ development
|
|
GS189692: GO:0045664 regulation of neuron differentiation
|
|
GS163286: MP:0008045 decreased NK cell number
|
|
GS188708: GO:0045787 positive regulation of cell cycle
|
|
GS208664: GO:0008283 cell proliferation
|
|
GS169173: MP:0006387 abnormal T cell number
|
|
GS186633: GO:0044093 positive regulation of molecular function
|
|
GS203594: GO:0043226 organelle
|
|
GS200432: GO:0002682 regulation of immune system process
|
|
GS205364: GO:0010467 gene expression
|
|
GS136397: organ weight 6 (Org6, Published QTL Chr 10)
|
|
GS185256: GO:0051251 positive regulation of lymphocyte activation
|
|
GS163450: MP:0001199 thin skin
|
|
GS194587: GO:0002377 immunoglobulin production
|
|
GS136076: insulin QTL 9 (Insq9, Published QTL Chr 10)
|
|
GS163559: MP:0008036 abnormal NK T cell morphology
|
|
GS163639: MP:0008208 decreased pro-B cell number
|
|
GS190949: GO:0009058 biosynthetic process
|
|
GS165537: MP:0005376 homeostasis/metabolism phenotype
|
|
GS165741: MP:0008475 intermingled spleen red and white pulp
|
|
GS198866: GO:0000785 chromatin
|
|
GS204657: GO:0016573 histone acetylation
|
|
GS203593: GO:0043227 membrane-bounded organelle
|
|
GS201265: GO:0009891 positive regulation of biosynthetic process
|
|
GS209887: GO:0050767 regulation of neurogenesis
|
|
GS177308: GO:1901362 organic cyclic compound biosynthetic process
|
|
GS127127: Benzo(a)pyrene interacting genes (MeSH:D001564) in CTD
|
|
GS166271: MP:0009582 abnormal keratinocyte proliferation
|
|
GS210000: GO:0044446 intracellular organelle part
|
|
GS168370: MP:0003453 abnormal keratinocyte physiology
|
|
GS168844: MP:0002458 abnormal B cell number
|
|
GS194605: GO:0001775 cell activation
|
|
GS202316: GO:0050789 regulation of biological process
|
|
GS194087: GO:0003674 molecular_function
|
|
GS191268: GO:0010033 response to organic substance
|
|
GS184461: GO:0009891 positive regulation of biosynthetic process
|
|
GS199389: GO:0019900 kinase binding
|
|
GS121343: Flavonoids interacting genes (MeSH:D005419) in CTD
|
|
GS178885: GO:0003677 DNA binding
|
|
GS167321: MP:0003945 abnormal lymphocyte physiology
|
|
GS135585: cholesterol absorption 2 (Chab2, Published QTL Chr 10)
|
|
GS180875: GO:0051249 regulation of lymphocyte activation
|
|
GS162979: MP:0002353 abnormal inguinal lymph node morphology
|
|
GS194336: GO:0043412 macromolecule modification
|
|
GS180166: GO:0008152 metabolic process
|
|
GS183553: GO:0016569 covalent chromatin modification
|
|
GS166208: MP:0008181 increased marginal zone B cell number
|
|
GS168347: MP:0008755 abnormal immunoglobulin V(D)J recombination
|
|
GS180673: GO:0044451 nucleoplasm part
|
|
GS209024: GO:0000988 protein binding transcription factor activity
|
|
GS170362: MP:0000717 abnormal lymphocyte cell number
|
|
GS195678: GO:0003700 sequence-specific DNA binding transcription factor activity
|
|
GS208604: GO:0001067 regulatory region nucleic acid binding
|
|
GS166862: MP:0000689 abnormal spleen morphology
|
|
GS136151: "lupus in MRL and B6 F2 cross, QTL 4" (Lmb4, Published QTL Chr 10)
|
|
GS195059: GO:0051147 regulation of muscle cell differentiation
|
|
GS165688: MP:0009630 absent axillary lymph nodes
|
|
GS168628: MP:0000378 absent hair follicles
|
|
GS186071: GO:0050871 positive regulation of B cell activation
|
|
GS209190: GO:0007049 cell cycle
|